Literature DB >> 10342367

Radioiodine is an effective, inexpensive, and safe treatment for Graves' hyperthyroidism, its immunological effects must be taken into account.

L Chiovato1, R Rocchi, E Fiore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10342367     DOI： 10.1007/BF03343562

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  9 in total

Review 1.  Radioiodine and the immune system.

Authors:  L J DeGroot
Journal:  Thyroid       Date:  1997-04       Impact factor: 6.568

2.  The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism.

Authors:  S Kubota; K Gunji; B A Ackrell; B Cochran; C Stolarski; S Wengrowicz; J S Kennerdell; Y Hiromatsu; J Wall
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

3.  Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies.

Authors:  A Pinchera; P Liberti; E Martino; G F Fenzi; L Grasso; L Rovis; L Baschieri; G Doria
Journal:  J Clin Endocrinol Metab       Date:  1969-02       Impact factor: 5.958

Review 4.  The management of hyperthyroidism.

Authors:  J A Franklyn
Journal:  N Engl J Med       Date:  1994-06-16       Impact factor: 91.245

5.  Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.

Authors:  L Chiovato; E Fiore; P Vitti; R Rocchi; T Rago; D Dokic; F Latrofa; C Mammoli; F Lippi; C Ceccarelli; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1998-01       Impact factor: 5.958

Review 6.  Retro-orbital autoimmunity.

Authors:  A E Heufelder
Journal:  Baillieres Clin Endocrinol Metab       Date:  1997-10

7.  Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245

8.  Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.

Authors:  L Chiovato; F Santini; P Vitti; G Bendinelli; A Pinchera
Journal:  Clin Endocrinol (Oxf)       Date:  1994-06       Impact factor: 3.478

9.  Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue.

Authors:  A Feliciello; A Porcellini; I Ciullo; G Bonavolontà; E V Avvedimento; G Fenzi
Journal:  Lancet       Date:  1993-08-07       Impact factor: 79.321
  9 in total
  2 in total

Review 1.  Radioiodine and thyroid-associated ophthalmopathy: from the myth to the reality.

Authors:  C Beckers
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  Effect of radioiodine therapy on the presence of autoantibodies against human thyroid and eye muscle fractions.

Authors:  I Molnár; C Balázs
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.